Trimethylamine N-Oxide Generated by the Gut Microbiota: Potential Atherosclerosis Treatment Strategies
- 1 October 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 28 (35) , 2914-2919
Abstract
Cardiovascular diseases (CVD) have become a disease burden that plagues the world, and a large proportion of the world's mortality currently stems from atherosclerotic CVD. In addition to traditional therapies, we need to find more therapeutic targets and strategies in scientific research to address this challenge. In recent years, as research on gut microbiota has continued, there has been a clearer understanding of the role that metabolites from gut microbes play during atherosclerosis (AS). A growing body of research suggests that trimethylamine oxide (TMAO) is an independent risk factor for CVD and that gut microbe-dependent TMAO plays a critical role in AS. Therefore, interventions targeting TMAO have the potential to become a new therapeutic strategy for AS. This review provides a brief overview of the relationship between TMAO and atherosclerosis. More importantly, several potential atherosclerosis treatment strategies targeting TMAO and its metabolic pathways have been revealed by recent studies and will be the focus of this review. This review summarizes possible therapeutic strategies in terms of change of diet, adjustment of gut microbiota, suppression of liver enzyme activity, and improvement of renal function, in the hope of providing new insights for developing efficient and cost-effective treatment and prevention for AS.Keywords
Funding Information
- National Natural Science Foundation of China (31771277)
This publication has 67 references indexed in Scilit:
- Transmission of Atherosclerosis Susceptibility with Gut Microbial TransplantationJournal of Biological Chemistry, 2015
- Gut Microbiota-Dependent Trimethylamine N -Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney DiseaseCirculation Research, 2015
- The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol BalanceCell Reports, 2015
- Impact of Postdischarge Statin Withdrawal on Long-Term Outcomes in Patients With Acute Myocardial InfarctionThe American Journal of Cardiology, 2015
- Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxideEuropean Heart Journal, 2014
- Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular RiskNew England Journal of Medicine, 2013
- Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosisNature Medicine, 2013
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature, 2011
- The safety of statins in clinical practiceThe Lancet, 2007
- Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndromeNature Genetics, 1997